En Pointe Technologies ( ENPT) shares were tanking after the computer-products distributor saw lower fiscal first-quarter sales -- $75.6 million, compared with $78.7 million last year -- due to sinking product revenue. The California-based outfit's bottom line was up year over year, with a profit of $272,000, or 4 cents a share, from losses of $997,000, or 14 cents a share, a year ago. Still, shares were sliding $1.62, or 25.9%, to $4.64. Envoy Communications ( ECGI) surged nearly 40% after it swung to a profit of $1.6 million, or 8 cents a share (US$1.4 million, or 7 cents), for the quarter ended Dec. 31. Last year the Canada-based marketing-services company lost $1.1 million, or a nickel a share. Shares were gaining $1.23, or 45.6%, to $3.93 on the Nasdaq. R.G. Barry ( DFZ) shot up after the Ohio-based footwear maker reported fiscal second-quarter profits of $20.3 million, or $1.96 a share, on sales that rose 11% from a year ago to $40.9 million. Last year the company made $4.8 million, or 46 cents a share. The company also upped its fiscal 2007 guidance, now foreseeing revenue growth of 6% to 8% vs. its previous prediction of a 5%-to-7% improvement. Shares were trading up $1.17, or 16.3%, to $8.36. Medical-equipment maker Cynosure ( CYNO) flew past Wall Street expectations for the fourth quarter, reporting earnings of $2.5 million, or 21 cents a share, excluding items, compared with $1.1 million, or 12 cents a share, a year ago. Analysts polled by Thomson Financial were seeking 16 cents a share. Revenue ratcheted up 52% to $24.6 million from last year, topping the $20.9 million mean estimate. The Westford, Mass., company was rising $1.69, or 8.2%, to $22.40.
California's AdStar ( ADST) was climbing on word it will conduct a trial on Nokia's ( NOK) S60 software platform for a service that can deliver advertising to mobile devices. AdStar shares were adding 19 cents, or 7.7%, to $2.67. Nokia was recently up 27 cents, or 1.2%, to $22.05. Seattle Genetics ( SGEN) rose after the Food and Drug Administration granted orphan drug status to its proposed treatments for acute myeloid leukemia and Hodgkin's disease. This means seven years of marketing exclusivity upon approval of the compounds, as well as various possible grants and tax credits during developmental stages. Shares were up 55 cents, or 6.3%, to $9.32. The Knot ( KNOT) fell after one-off items constituted most of its fourth-quarter income of $14.6 million, or 45 cents a share. The New York-based wedding Web site operator earned $1.5 million, or 6 cents a share, a year ago. Revenue leapt 70% year over year to $21.7 million. Shares were losing $4.36, or 14.5%, to $25.71 Osiris Therapeutics ( OSIR) was lower after the Baltimore-based biotech reported the failure of its meniscus-regeneration adult-stem-cell formulation, Chondrogen, in phase I/II testing on patients who had just undergone surgery to have damaged tissue removed from the meniscus in their knees. The company noted that, while meniscus-tissue amounts didn't increase, there was an improvement in baseline cartilage and joint condition, and that the treatment was well tolerated. Shares were off $2.58, or 12.6%, to $17.97. Radyne ( RADN) dropped on thinning fourth-quarter profits. The communications-equipment maker posted earnings of $3.6 million, or 19 cents a share, on slightly lower revenue of $36.3 million. Last year it had a profit of $4.3 million, or 24 cents a share. Radyne stock was trailing $1.19, or 11.2%, to $9.40. Palatin Technologies ( PTN) said it will offer 13.75 million of its shares at $2 apiece, with net proceeds expected around $25.5 million. The offer will close on or around Feb. 15. Shares were down 23 cents, or 10%, to $2.06.